Janux Therapeutics, Inc.

XNASHealth care

Last traded price · USD

$18.18

+0.00%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 16:00 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $18.18
Volume: 56
Day's high: —
Day's low: —

In brief

Janux Therapeutics, Inc. is a health care company listed on Nasdaq, valued at about $1.11B.
Its shares closed at $18.18 on 4 Nov 2026, down 32.7% over the past year.
From India you can buy JANX in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Janux Therapeutics, Inc. (JANX) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole JANX share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade JANX options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: +8.3% (SPY −1.6%, XLV +13.5%). 3 months: +13.6% (SPY −0.4%, XLV +15.5%). 1 year: −32.7% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: JANX, SPY and XLV · as of 4 Nov 2026
6.2 days to cover short interest
5.3M shares were sold short at the 15 Oct 2026 settlement, 8.7% of the 61.1M shares outstanding; covering them would take 6.2 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $18.18 was 3.5% above its 50-day average ($17.57) and 18.1% above its 200-day average ($15.39). It has closed above the 200-day for 57 sessions, since 17 Aug 2026. The 50-day average crossed above the 200-day on 26 Aug 2026, 49 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
26% of the way up its 52-week range
Closed at $18.18 on 4 Nov 2026: 48.6% below the 52-week high of $35.34 (26 Nov 2025) and 50.0% above the low of $12.12 (5 Feb 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+8.3%

6 months+24.4%

1 year−32.7%

5 years−31.9%

Newswire

About

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Website

Notable moves

December 2, 2025
−53.34%
December 3, 2024
+48.98%
February 27, 2024
+229.47%

Newswire

About

Website

Notable moves

December 2, 2025
−53.34%
December 3, 2024
+48.98%
February 27, 2024
+229.47%

Janux Therapeutics, Inc.

XNASHealth care

Last traded price · USD

$18.18

+0.00%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 16:00 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $18.18
Volume: 56
Day's high: —
Day's low: —

In brief

Janux Therapeutics, Inc. is a health care company listed on Nasdaq, valued at about $1.11B.
Its shares closed at $18.18 on 4 Nov 2026, down 32.7% over the past year.
From India you can buy JANX in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Janux Therapeutics, Inc. (JANX) shares from India?

Do I need the price of a whole JANX share to invest?

How much can I invest in US stocks in a year?

Can I trade JANX options or futures?

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: +8.3% (SPY −1.6%, XLV +13.5%). 3 months: +13.6% (SPY −0.4%, XLV +15.5%). 1 year: −32.7% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: JANX, SPY and XLV · as of 4 Nov 2026
6.2 days to cover short interest
5.3M shares were sold short at the 15 Oct 2026 settlement, 8.7% of the 61.1M shares outstanding; covering them would take 6.2 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $18.18 was 3.5% above its 50-day average ($17.57) and 18.1% above its 200-day average ($15.39). It has closed above the 200-day for 57 sessions, since 17 Aug 2026. The 50-day average crossed above the 200-day on 26 Aug 2026, 49 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
26% of the way up its 52-week range
Closed at $18.18 on 4 Nov 2026: 48.6% below the 52-week high of $35.34 (26 Nov 2025) and 50.0% above the low of $12.12 (5 Feb 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+8.3%

6 months+24.4%

1 year−32.7%

5 years−31.9%

Newswire

About

Website

Notable moves

December 2, 2025
−53.34%
December 3, 2024
+48.98%
February 27, 2024
+229.47%

Newswire

About

Website

Notable moves

December 2, 2025
−53.34%
December 3, 2024
+48.98%
February 27, 2024
+229.47%

Janux Therapeutics, Inc.

Janux Therapeutics, Inc. in brief

Behind SPY and its sector fund XLV over 1 year

6.2 days to cover short interest

Above its 50- and 200-day averages

26% of the way up its 52-week range

Janux Therapeutics, Inc.

Janux Therapeutics, Inc. in brief

Behind SPY and its sector fund XLV over 1 year

6.2 days to cover short interest

Above its 50- and 200-day averages

26% of the way up its 52-week range